PipelineReview.com10h
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
COPENHAGEN, Denmark I April 2, 2025 I Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, ...
PipelineReview.com10h
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
SHANGHAI, China I April 2, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ...
PipelineReview.com10h
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...
PipelineReview.com1d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
NEW YORK, NY, USA I April 01, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
PipelineReview.com1d
Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma
CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable ...
PipelineReview.com1d
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
STAFFORD, TX, USA I April 02, 2025 I Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its ...
PipelineReview.com1d
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
MELBOURNE, Australia I April 02, 2025 I Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has ...
PipelineReview.com1d
Desentum Reports Strong Safety and Immunological Data From Phase 1 Clinical Study With Investigational Birch Pollen Allergy Vaccine DM-101PX
ESPOO, Finland I April 01, 2025 I Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces ...
PipelineReview.com1d
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
LAUSANNE, Switzerland I April 2, 2025 I AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for ...
PipelineReview.com1d
Gubra announces positive GUBamy Phase 1 interim MAD results
Doses of 1 mg and 2 mg GUBamy administered once-weekly for six weeks led to a dose dependent mean weight loss. LS Mean weight loss in the 2 mg cohort was -7.77% on day 43. In the placebo group there ...
PipelineReview.com1d
AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline
Financing led by Venrock Healthcare Capital Partners with co-lead Forbion Growth, and participation from RTW Investments, Nextech Invest, and other new ...
PipelineReview.com1d
ESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatment
BARCELONA, Spain I April 1, 2025 I ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals with global rights for Increlex®, except for ...